TARBP2 and hepatocellular carcinoma: To determine the function of TARBP2 in sorafenib resistance in HCC cells, TARBP2‐overexpressing HCC cells were treated with sorafenib at the indicated concentrations (0, 2, 5, 10, and 20 μm) for 48 h (Fig. 2A,B).